Response Patterns of EGb 761® in Alzheimer’s Disease: Influence of Neuropsychological Profiles

We conducted an exploratory analysis of the influence of baseline neuropsychological (NP) profiles on the effect of EGb 761® (definition see editorial) in Alzheimer’s disease (AD). Using this perspective, we stratified the intent-to-treat data set collected during a 52-week, randomized, double-blind, placebo-controlled study with 120 mg EGb 761® based on cut-off points applied to naming and constructional praxis items of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog). Mean changes over baseline and percentage of responders in each NP group and overall efficacy were analyzed, using the ADAS-Cog subscale as outcome measurements for assessing cognitive performance and the Geriatric Evaluation using the Relative’s Rating Instrument (GERRI) to measure social functioning. Three subgroups were identified: (1) right AD (RAD) subgroup, including 83 patients with primarily visual-constructional impairment; (2) left AD (LAD) with 25 patients showing predominant verbal deficits; (3) general AD (GAD) including 60 patients impaired in both cognitive domains. At the endpoint, the EGb 761® group of RAD showed an improvement of 1.7 points according to ADAS-Cog and 0.15 points according to GERRI, while the placebo group worsened by 1.3 and 0.02 points, respectively. The LAD patients worsened regardless of treatment; however, to a lesser degree in those receiving EGb 761® as assessed by the increase of 4.7 ADAS-Cog points and 0.13 GERRI points compared to 6.8 points and 0.20 points, respectively, for placebo. In GAD, the EGb 761® group showed minimal changes, whereas the placebo group slightly worsened on both assessments, resulting in favorable treatment differences of 1.6 ADAS-Cog points and 0.23 GERRI points. Retrospective analysis of overall efficacy indicated that a quantitative treatment effect favorable to EGb 761® could be observed in cognitive performance (p = 0.04) and social functioning (p = 0.02), even taking NP differences and baseline severity into account. However, qualitative EGb 761® effects could greatly depend on NP profiles - improvement could be expected with RAD patients, while EGb 761® effect should be considered more in terms of stabilization for GAD and delayed worsening for LAD population.

Ginkgo - EGb 761® - Alzheimer’s disease - Neuropsychological profiles

References

• 1 Becker J T, Huff F J, Nebes R D, Holland A, Boller F. Neuropsychological function in Alzheimer’s disease: Pattern of impairment and rate of progression.  Arch Neurol. 1988;  45 263-268
• 2 DeFeudis F .V. Ginkgo biloba Extract (EGb 761®): From chemistry to the clinic. DeFeudis FV ed Ullstein Medical Wiesbaden; 1998
• 3 Fisher N J, Rourke B P, Bieliauskas L A. Neuropsychological Subgroups of Patients with Alzheimer’s Disease: An Examination of First 10 Years of CERAD Data.  J Clin Exp Neuropsychol. 1999;  21 488-518
• 4 Kanowski S, Herrmann W M, Stephan K, Wierich W, Hörr R. Proof of Efficacy of the Ginkgo biloba Special Extract EGb 761® in Outpatients Suffering from Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Multi-Infarct Dementia.  Pharmacopsychiatry. 1996;  29 47-56
• 5 Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency.  Br J Clin Pharmacol. 1992;  34 352-358
• 6 Le Bars P L, Katz M M, Berman N, Itil T M, Freedman A M, Schatzberg A F. A Placebo-Controlled, Double-Blind, Randomized Trial of an Extract of Ginkgo biloba for Dementia.  JAMA. 1997;  278 1327-1332
• 7 Le Bars P L, Velasco F M, Ferguson J M, Dessain E C, Kieser M, Hoerr R. Influence of the Severity of Cognitive Impairment on the Effect of the Ginkgo biloba Extract EGb 761® in Alzheimer’s Disease.  Neuropsychobiology. 2002;  45 19-26
• 8 Letzel H, Haan J, Feil W B. Nootropics: Efficacy and tolerability of products from three active substance classes.  J Drug Dev Clin Pract. 1996;  8 77-94
• 9 Martin A, Brouwers P, Lalonde F, Cox C, Teleska P, Fedio P, Foster N L, Chase T N. Towards a behavioral typology of Alzheimer’s patients.  J Clin Exp Neuropsychol. 1986;  8 594-610
• 10 Neary D, Snowden J S, Bowen D M, Sims N R, Mann D, Benton J S, Northen B, Yates P, Avison D. Neuropsychological syndromes in presenile dementia due to cerebral atrophy.  J Neurol Neurosurg Neuropsychiat. 1986;  49 163-174
• 11 Oken B S, Storzbach D M, Kaye J A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.  Arch Neurol. 1998;  55 1409-1415
• 12 Rosen W G, Mohs R C, Davis K L. A new rating scale for Alzheimer’s disease.  Am J Psychiatry. 1984;  141 1356-1364
• 13 Schwartz G E. Development and validation of the Geriatric Evaluation by Relative’s Rating Instrument (GERRI).  Psychological Reports. 1983;  53 479-488
• 14 Stern R G, Mohs R C, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis K L. A Longitudinal Study of Alzheimer’s Disease: Measurement, Rate, and Predictors of Cognitive Deterioration.  Am J Psychiatry. 1994;  151 390-396
• 15 Strite D, Massman P J, Cooke N, Doody R S. Neuropsychological asymmetry in Alzheimer’s disease: Verbal versus visuoconstructional deficits across stages of dementia.  J Int Neuropsychol Soc. 1997;  3 420-427